EMA Authorised: Erleada (apalutamide) — Janssen-Cilag International NV

View source ↗

Summary

The EMA authorised Erleada (apalutamide) for prostate cancer, under Janssen-Cilag International NV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Janssen-Cilag International NV. Decision date: 12/03/2026